BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 9753314)

  • 1. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
    Farmer RD; Lawrenson RA
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S78-86. PubMed ID: 9753314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
    Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women.
    Lewis MA; Heinemann LA; Spitzer WO; MacRae KD; Bruppacher R
    Contraception; 1997 Sep; 56(3):129-40. PubMed ID: 9347202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-time use of newer oral contraceptives and the risk of venous thromboembolism.
    Suissa S; Blais L; Spitzer WO; Cusson J; Lewis M; Heinemann L
    Contraception; 1997 Sep; 56(3):141-6. PubMed ID: 9347203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR; Ory H
    Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venous thromboembolism and desogestrel- or gestodene-containing combination oral contraceptives: what are the facts?
    Contracept Rep; 1996 Apr; 7(1):3-6. PubMed ID: 12320047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of oral contraceptive progestins on serum copper concentration.
    Berg G; Kohlmeier L; Brenner H
    Eur J Clin Nutr; 1998 Oct; 52(10):711-5. PubMed ID: 9805216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study.
    Farmer RD; Todd JC; Lewis MA; MacRae KD; Williams TJ
    Contraception; 1998 Feb; 57(2):67-70. PubMed ID: 9589831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombotic diseases in young women and the influence of oral contraceptives.
    Lidegaard O
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S62-7. PubMed ID: 9753312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
    Winkler UH
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bias versus causality: interpreting recent evidence of oral contraceptive studies.
    Spitzer WO
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S43-50. PubMed ID: 9753310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern oral contraceptives and cardiovascular disease.
    Rosenberg L; Palmer JR; Sands MI; Grimes D; Bergman U; Daling J; Mills A
    Am J Obstet Gynecol; 1997 Sep; 177(3):707-15. PubMed ID: 9322646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer oral contraceptives and the risk of venous thromboembolism.
    Walker AM
    Contraception; 1998 Mar; 57(3):169-81. PubMed ID: 9617533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
    Spitzer WO; Lewis MA; Heinemann LA; Thorogood M; MacRae KD
    BMJ; 1996 Jan; 312(7023):83-8. PubMed ID: 8555935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial infarction and stroke in young women: what is the impact of oral contraceptives?
    Lewis MA
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S68-77. PubMed ID: 9753313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF; Crook D; Devenport M; Wynn V
    Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.